Monday 22 October 2012

Actavis CEO: originators to have edge in "biosimilars"

FRANKFURT (Reuters) - The market for cheap copies of biotech drugs could initially be dominated by the very companies that develop these drugs, rather than established generic drug makers, the outgoing head of Switzerland's Actavis said. The m...

Source: http://health.yahoo.net/news/s/nm/actavis-ceo-originators-to-have-edge-in-biosimilars

more information more info info example

No comments:

Post a Comment

Note: only a member of this blog may post a comment.